[HTML][HTML] Emicizumab in acquired hemophilia A: Pros and cons of a new approach to the prevention and treatment of bleeding
S Pasca, E Zanon, PM Mannucci, F Peyvandi - Blood Transfusion, 2023 - ncbi.nlm.nih.gov
Emicizumab, a monoclonal bispecific antibody that mimics the function of activated factor VIII
(FVIII), is currently licensed for prophylactic use in patients with congenital hemophilia A with …
(FVIII), is currently licensed for prophylactic use in patients with congenital hemophilia A with …
[PDF][PDF] Emicizumab in acquired hemophilia A: pros and cons of a new approach to the prevention and treatment of bleeding
T Center, FL Villa - researchgate.net
Emicizumab, a monoclonal bispecific antibody that mimics the function of activated factor VIII
(FVIII), is currently licensed for prophylactic use in patients with congenital hemophilia A with …
(FVIII), is currently licensed for prophylactic use in patients with congenital hemophilia A with …
[引用][C] Emicizumab in acquired hemophilia A: pros and cons of a new approach to the prevention and treatment of bleeding
S Pasca, E Zanon, PM Mannucci… - BLOOD …, 2023 - research.unipd.it
Emicizumab in acquired hemophilia A: pros and cons of a new approach to the prevention and
treatment of bleeding IRIS IRIS Home Sfoglia Macrotipologie & tipologie Autore Titolo Riviste …
treatment of bleeding IRIS IRIS Home Sfoglia Macrotipologie & tipologie Autore Titolo Riviste …
Emicizumab in acquired hemophilia A: pros and cons of a new approach to the prevention and treatment of bleeding.
S Pasca, E Zanon, PM Mannucci… - … = Trasfusione del Sangue, 2023 - europepmc.org
Emicizumab, a monoclonal bispecific antibody that mimics the function of activated factor VIII
(FVIII), is currently licensed for prophylactic use in patients with congenital hemophilia A with …
(FVIII), is currently licensed for prophylactic use in patients with congenital hemophilia A with …
Emicizumab in acquired hemophilia A: pros and cons of a new approach to the prevention and treatment of bleeding: Emicizumab in acquired hemophilia A
S Pasca, E Zanon, PM Mannucci… - Blood Transfusion, 2023 - bloodtransfusion.it
Emicizumab, a monoclonal bispecific antibody that mimics the function of activated factor VIII
(FVIII), is currently licensed for prophylactic use in patients with congenital hemophilia A with …
(FVIII), is currently licensed for prophylactic use in patients with congenital hemophilia A with …
Emicizumab in acquired hemophilia A: pros and cons of a new approach to the prevention and treatment of bleeding
S Pasca, E Zanon, PM Mannucci… - Blood transfusion …, 2023 - pubmed.ncbi.nlm.nih.gov
Emicizumab, a monoclonal bispecific antibody that mimics the function of activated factor VIII
(FVIII), is currently licensed for prophylactic use in patients with congenital hemophilia A with …
(FVIII), is currently licensed for prophylactic use in patients with congenital hemophilia A with …
[PDF][PDF] Emicizumab in acquired hemophilia A: pros and cons of a new approach to the prevention and treatment of bleeding
S Pasca, E Zanon, PM Mannucci… - An overview on …, 2023 - cris.maastrichtuniversity.nl
Emicizumab, a monoclonal bispecific antibody that mimics the function of activated factor VIII
(FVIII), is currently licensed for prophylactic use in patients with congenital hemophilia A with …
(FVIII), is currently licensed for prophylactic use in patients with congenital hemophilia A with …
[PDF][PDF] Emicizumab in acquired hemophilia A: pros and cons of a new approach to the prevention and treatment of bleeding
FL Villa - scholar.archive.org
Emicizumab, a monoclonal bispecific antibody that mimics the function of activated factor VIII
(FVIII), is currently licensed for prophylactic use in patients with congenital hemophilia A with …
(FVIII), is currently licensed for prophylactic use in patients with congenital hemophilia A with …
Emicizumab in acquired hemophilia A: pros and cons of a new approach to the prevention and treatment of bleeding.
S Pasca, E Zanon, PM Mannucci… - … = Trasfusione del Sangue, 2023 - europepmc.org
Emicizumab, a monoclonal bispecific antibody that mimics the function of activated factor VIII
(FVIII), is currently licensed for prophylactic use in patients with congenital hemophilia A with …
(FVIII), is currently licensed for prophylactic use in patients with congenital hemophilia A with …